A Study to Evaluate the Effect of the Combination of Umeclidinium (UMEC) and Vilanterol (VI) on Exercise Endurance Time (EET) in Participants With Chronic Obstructive Pulmonary Disease (COPD)

Inclusion Criteria:

- Type of participant: Outpatient.

- Informed Consent: A signed and dated written informed consent prior to study
participation.

- Age: 40 years of age or older at Visit 1.

- Gender: Male or female participants. A female is eligible to enter and participate in
the study if she is of: Non-child bearing potential (i.e. physiologically incapable of
becoming pregnant, including any female who is post-menopausal or surgically sterile).
Surgically sterile females are defined as those with a documented hysterectomy and/or
bilateral oophorectomy or tubal ligation. Post-menopausal females are defined as being
amenorrhoeic for greater than 1 year with an appropriate clinical profile, e.g. age
appropriate, >45 years, in the absence of hormone replacement therapy. OR Child
bearing potential, has a negative pregnancy test at screening, and agrees to one of
the following acceptable contraceptive methods used consistently and correctly (i.e.
in accordance with the approved product label and the instructions of the physician
for the duration of the study - screening to follow-up contact): Abstinence; Oral
Contraceptive, either combined or progestogen alone; Injectable progestogen; Implants
of levonorgestrel; Estrogenic vaginal ring; Percutaneous contraceptive patches;
Intrauterine device (IUD) or intrauterine system (IUS) that meets the standard
operating procedures (SOP); effectiveness criteria as stated in the product label;
Male partner sterilization (vasectomy with documentation of azoospermia) prior to the
female participant's entry into the study, and this male is the sole partner for that
subject. For this definition, "documented" refers to the outcome of the
investigator's/designee's medical examination of the participant or review of the
participant's medical history for study eligibility, as obtained via a verbal
interview with the participant or from the participant's medical records; Double
barrier method: condom and an occlusive cap (diaphragm or cervical/vault caps) with a
vaginal spermicidal agent (foam/gel/film/cream/suppository)

- Diagnosis: A diagnosis of COPD in accordance with the definition by the American
Thoracic Society/European Respiratory Society

- Smoking History: Current or former cigarette smokers with a history of cigarette
smoking of >=10 pack-years (number of pack years =[number of cigarettes per day /20] x
number of years smoked [e.g., 20 cigarettes per day for 10 years, or 10 cigarettes per
day for 20 years]). Former smokers are defined as those who have stopped smoking for
at least 6 months prior to Visit 1.

- Severity of Disease: A pre- and post-albuterol Forced Expiratory Volume in One
Second/Forced Vital Capacity (FEV1/FVC) ratio of <0.70 and a postalbuterol FEV1 of
>=30% and <=70% of predicted normal values

- Dyspnea: A score of >=2 on the Modified Medical Research Council Dyspnea Scale (mMRC)
at Visit 1.

- Resting Lung Volumes: A resting FRC of >=120% of predicted normal FRC at Visit 1.
Predicted values for FRC will be obtained using predicted normal values

Exclusion Criteria:

- Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant
during the study.

- Asthma: A current diagnosis of asthma.

- Other Respiratory Disorders Known alpha-1 antitrypsin deficiency, active lung
infections (such as tuberculosis), and lung cancer in remission for <5 years are
absolute exclusionary conditions. A participant who, in the opinion of the
investigator, has any other significant respiratory conditions in addition to COPD
should be excluded. Examples may include clinically significant bronchiectasis,
pulmonary hypertension, sarcoidosis, or interstitial lung disease. Allergic rhinitis
is not exclusionary.

- Other Diseases/Abnormalities: Any participant who is considered unlikely to survive
the duration of the study period or has any rapidly progressing disease or immediate
life-threatening illness (e.g. cancer). In addition, any participant who has any
condition besides COPD that is likely to affect respiratory function or the ability to
perform exercise testing such as peripheral vascular disease should not be included in
the study.

- Severe Hepatic Impairment: Patients with severe hepatic impairment (Child-Pugh class
C) should be excluded unless, in the opinion of the investigator, the benefit is
likely to outweigh the risk.

- Unstable or life threatening cardiac disease: Umeclidinium/vilanterol should be used
with caution in participants with severe cardiovascular disease. In the opinion of the
investigator, use should only be considered if the benefit is likely to outweigh the
risk in conditions such as: Myocardial infarction or unstable angina in the last 6
months; Unstable or life threatening cardiac arrhythmia requiring intervention in the
last 3 months; New York Heart Association (NYHA) Class IV heart failure

- Contraindications: Any history of allergy or hypersensitivity to any
anticholinergic/muscarinic receptor antagonist, beta2-agonist, sympathomimetic,
lactose/milk protein or magnesium stearate.

- Antimuscarinic effects: Participants with medical conditions such as narrow-angle
glaucoma, urinary retention, prostatic hypertrophy, or bladder neck obstruction should
only be included if, in the opinion of the study physician, the benefit outweighs the
risk.

- Hospitalization: Hospitalization for COPD or pneumonia within 12 weeks prior to Visit
1

- Lung Resection: Participants with lung volume reduction surgery within the 12 months
prior to Screening (Visit 1).

- 12-Lead Electrocardiogram (ECG): Investigators will be provided with ECG reviews
conducted by a centralized independent cardiologist to assist in evaluation of
participant eligibility. The Investigator will determine the clinical significance of
each abnormal ECG finding in relation to the participant's medical history and exclude
participants who would be at undue risk by participating in the trial. Participants
with the following abnormalities are excluded from participation in the study: Atrial
fibrillation with rapid ventricular rate >120 beats per minute (bpm); Sustained or
nonsustained ventricular tachycardia; Second degree heart block Mobitz type II and
third degree heart block (unless pacemaker or defibrillator had been inserted)

- Medication Prior to Spirometry: Unable to withhold albuterol for the 4 hour period
required prior to spirometry testing at each study visit

- Interactions: Concomitant administration with beta-blockers or strong Cytochrome P450
3A4 (CYP3A4) inhibitors is only permitted if, in the Investigator's opinion, the
likely benefit outweighs the potential risk

- Medications prior to Screening: Use of the following medications according to the
following defined time intervals prior to Visit 1: Depot corticosteroids (12 weeks),
systemic, oral or parenteral corticosteroids (Intra-articular and epidural
corticosteroid injections are permitted) (6 weeks), antibiotics (for lower respiratory
tract infection and/or COPD exacerbation) (6 weeks), long-acting beta agonist (LABA)/
inhaled corticosteroid (ICS) combination products if LABA/ICS therapy is discontinued
completely (30 days), LABA/ICS combination products only if discontinuing LABA therapy
and switching to ICS monotherapy (dose of ICS that is switched to must not exceed
1000mcg of fluticasone propionate or equivalent) (48 hours for the salmeterol or
formoterol component 14 days for the vilanterol component), use of ICS at a dose >1000
microgram (mcg)/day of fluticasone propionate or equivalent (Use of ICS is permitted
provided the dose does not exceed 1000mcg of fluticasone propionate or equivalent; ICS
use not to be initiated or discontinued within 30 days prior to Visit 1 except for
participants on LABA/ICS therapy who may discontinue LABA/ICS therapy as indicated and
switch to ICS monotherapy) (30 days), initiation or discontinuation of ICS use (30
days), Phosphodiesterase 4 (PDE4) inhibitor (roflumilast) (14 days), Inhaled long
acting beta2 agonists (LABA): salmeterol, formoterol (48 hours); olodaterol,
indacaterol (14 days), Long-acting muscarinic antagonists (tiotropium, aclidinium,
glycopyrronium, umeclidinium) (7 days), LAMA/LABA combination products (whichever mono
component has the longest washout), theophyllines (48 hours), oral beta2-agonists
(long-acting [48 hours], short-acting [12 hours]), inhaled short acting beta2-agonists
(study provided prn albuterol/ is permitted during the study, except in the 4-hour
period prior to spirometry testing) (4 hours), inhaled short-acting anticholinergics
(permitted during the run-in period between Visits 1 and 4 and washout period between
Visits 7 and 9. Participants must discontinue use of short-acting anticholinergics at
least 4 hours before Visit 4 and Visit 9. Participants should not use short acting
anticholinergics during the double-blind treatment periods) (4 hours), inhaled
short-acting anticholinergic/short-acting beta2-agonist combination products (4
hours), and any other investigational medication (30 days or within 5 drug half-lives
[whichever is longer])

- Oxygen: Use of long-term oxygen therapy (LTOT) described as oxygen therapy prescribed
for greater than 12 hours a day. As-needed oxygen use (i.e., <=12 hours per day) is
not exclusionary.

- Nebulized Therapy: Regular use (prescribed for use every day, not for as-needed use)
of short-acting bronchodilators (e.g., albuterol) via nebulized therapy

- Pulmonary Rehabilitation Program: Participation in the acute phase of a pulmonary
rehabilitation program within 4 weeks prior to Visit 1. Participants who are in the
maintenance phase of a pulmonary rehabilitation program are not excluded.

- Drug or Alcohol Abuse: A known or suspected history of alcohol or drug abuse within 2
years prior to Visit 1.

- Affiliation with Investigator Site: Is an investigator, sub-investigator, study
coordinator, employee of a participating investigator or study site, or immediate
family member of the aforementioned that is involved in this study.

- Inability to read: In the opinion of the Investigator, any participant who is unable
to read and/or would not be able to complete a questionnaire

- Participation in Previous Exercise Studies: Participants who have previously been
assigned a participant number (enrolled) in GlaxoSmithKline studies DB2114417 or
DB2114418.